Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Advisory Committees

Hematology and Pathology Devices Panel Meeting - July 18, 2008

On July 18, 2008, the Hematology and Pathology Devices Advisory Panel met to provide recommendations to the U.S. Food and Drug Administration (FDA) on issues relevant to granting CLIA waiver status to the automated hematology complete blood count (CBC) with differential cell count. The panel provided recommendations on whether this type of device would be appropriate for use in a CLIA waived setting along with specific recommendations regarding the FDA pre-analytical, analytical, and post-analytical questions.

The Open Public Hearing session gave the public an opportunity to provide input on this issue. Three speakers addressed the panel. The first recommended the panel not find the CBC with differential eligible for waiver because of the potential for harm from use in settings without conventional laboratory controls or regulation. The second two both spoke to the value of having a waived test to increase access to valuable laboratory information.

Contact: Louise E. Magruder, Executive Secretary; 240-276-1248; or

Transcripts may be purchased from: (written requests only)

Free State Court Reporting, Inc
1378 Cape St. Clair Road
Annapolis, MD 21409


Food and Drug Administration
Freedom of Information Staff (FOI)
5600 Fishers Lane, HFI-35
Rockville, MD 20852
301-827-6500 (voice), 301-443-1726 (fax)

Page Last Updated: 08/05/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English